Literature DB >> 7202472

Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets.

M Eichelbaum, H J Dengler, A Somogyi, G E von Unruh.   

Abstract

Although the absorption of verapamil is almost complete after oral administration, its bioavailability is low due to extensive hepatic first-pass metabolism. Besides large interindividual differences in first-pass metabolism, pronounced day-to-day intraindividual variations in first-pass metabolism are observed, leading to erroneous results in relative bioavailability studies. Stable isotope techniques, which permit simultaneous administration of a solution and a tablet, can successfully be used to overcome these difficulties. The method has the advantage that two experiments can be carried out in a single test. Furthermore, the number of subjects required in bioavailability studies can be greatly reduced. Using this technique the bioavailability of verapamil tablets (Isoptin 80) relative to a stable labelled solution of verapamil was found to be 108.1%, with a 95% confidence interval between 89.1 and 127.1%.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7202472     DOI: 10.1007/bf00568399

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  [Treatment of hypertrophic obstructive cardiomyopathy with verapamil, a calcium antagonist (author's transl)].

Authors:  M Kaltenbach; R Hopf; M Keller
Journal:  Dtsch Med Wochenschr       Date:  1976-08-27       Impact factor: 0.628

2.  Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method.

Authors:  J M Strong; J S Dutcher; W K Lee; A J Atkinson
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

3.  Intraindividual variation in drug disposition.

Authors:  A P Alvares; A Kappas; J L Eiseman; K E Anderson; C B Pantuck; E J Pantuck; K C Hsiao; W A Garland; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1979-10       Impact factor: 6.875

4.  Determination of verapamil in human plasma by mass fragmentography using stable isotope-labelled verapamil as internal standard.

Authors:  B Spiegelhalder; M Eichelbaum
Journal:  Arzneimittelforschung       Date:  1977

Review 5.  Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil.

Authors:  M R Rosen; A L Wit; B F Hoffman
Journal:  Am Heart J       Date:  1975-05       Impact factor: 4.749

6.  Assessment of verapamil in the treatment of angina pectoris.

Authors:  F Andreasen; E Boye; E Christoffersen; P Dalsgaard; E Henneberg; A Kallenbach; S Ladefoged; K Lillquist; E Mikkelsen; E Norder0; J Olsen; J K Pedersen; V Pedersen; G B Petersen; J Schroll; H Schultz; J Seidelin
Journal:  Eur J Cardiol       Date:  1975-04

7.  Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil.

Authors:  M Eichelbaum; A Somogyi; G E von Unruh; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

8.  The metabolism of DL-[14C]verapamil in man.

Authors:  M Eichelbaum; M Ende; G Remberg; M Schomerus; H J Dengler
Journal:  Drug Metab Dispos       Date:  1979 May-Jun       Impact factor: 3.922

9.  Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: increasing the power of bioavailability tests.

Authors:  H A Heck; S E Buttrill; N W Flynn; R L Dyer; M Anbar; T Cairns; S Dighe; B E Cabana
Journal:  J Pharmacokinet Biopharm       Date:  1979-06

10.  Physiological disposition of verapamil in man.

Authors:  M Schomerus; B Spiegelhalder; B Stieren; M Eichelbaum
Journal:  Cardiovasc Res       Date:  1976-09       Impact factor: 10.787

View more
  15 in total

Review 1.  Stable isotopes in clinical pharmacokinetic investigations. Advantages and disadvantages.

Authors:  T R Browne
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

2.  Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration.

Authors:  G Mikus; C Fischer; B Heuer; C Langen; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

3.  Estimation of the absolute bioavailability of flecainide using stable isotope technique.

Authors:  K Hage; K Bühl; C Fischer; N G Knebel
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.

Authors:  M Eichelbaum; A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 5.  Application of stable labelled drugs in clinical pharmacokinetic investigations.

Authors:  M Eichelbaum; G E von Unruh; A Somogyi
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

6.  Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data.

Authors:  A Somogyi; M Eichelbaum; R Gugler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment.

Authors:  M Eichelbaum; P Birkel; E Grube; U Gütgemann; A Somogyi
Journal:  Klin Wochenschr       Date:  1980-09-15

8.  Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.

Authors:  M Eichelbaum; G Mikus; B Vogelgesang
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

10.  Verapamil and norverapamil in plasma and breast milk during breast feeding.

Authors:  P Anderson; U Bondesson; I Mattiasson; B W Johansson
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.